摘要
Abstract
Objective:To investigate the clinical efficacy of mouse nerve growth factor (NGF) for treatment of pa-tients with anterior ischemic optic neuropathy (AION). Methods: Sixty-eight patients (70 eyes) with AION were randomly divided into control group and NGF group. All patients received the conventional treatment for AION. The cases in the NGF group were daily given the mouse NGF intramuscular injection combined with conventional treatment. All patients have been treated for four weeks. The clinical efficacy, visual acuity, visual field and visual evoked potentials situation and the nerve fiber thickness surrounding papilla optica were observed and compared. Results: After 4 weeks’treatment, the clinical efficacy of NGF group was significantly better than that in the con-trol group (P<0.05). The acuity and visual field of cases in the both groups were improved compared with those be-fore treatment and the acuity in the NGF group showed greater improvement than that in the control group (P<0. 05). The P100 wave latency in the NGF group was shorter than that before treatment and that in the control group (P<0.05). Before treatment, the nerve fiber thickness surrounding papilla optica in the both groups was thicker than the normal value (98.25±8.49) μm (P<0.05). The thickness was decreased after treatment (P<0.05), the data of thickness in the NGF group was higher than that in the control group (P<0.05). The thickness in the control group was lower than the normal value (P<0.05). Conclusion: Mouse NGF is an effective way to treat AION, which can significantly improve the clinical efficacy, acuity, visual field, and visual evoked potential recovery and reduce the peripapillary nerve fiber atrophy.关键词
鼠神经生长因子/前部缺血性视神经病变/临床疗效Key words
mouse nerve growth factor/anterior ischemic optic neuropathy/clinical efficacy分类
医药卫生
